CHRISTABEL KHAEMBA

Dr. CHRISTABEL KHAEMBA

P
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
ABAbbie Barry
Abbie Barry
SOSten Olsson
Sten Olsson
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
JKJoseph Kabatende
Joseph Kabatende
Tigist DiresTigist Dires
Tigist Dires
EAEleni Aklillu
Eleni Aklillu
Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination; (ii) data management and signal generation; (iii) risk assessment and evaluation; and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.

15 March 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
ABAbbie Barry
Abbie Barry
WOWyckliff Omondi
Wyckliff Omondi
KBKefa Bota
Kefa Bota
SMSultani Matendechero
Sultani Matendechero
EAEleni Aklillu
Eleni Aklillu
Preventive chemotherapy with diethylcarbamazine citrate (DEC) and albendazole (ALB) is the core intervention strategy to eliminate lymphatic filariasis (LF). We conducted a large-scale prospective active safety surveillance study to identify the incidence, type, severity, and risk factors for adverse events (AEs) following mass drug administration (MDA) of single-dose DEC and ALB in 10,010 participants from Kilifi County, Kenya. AEs were actively monitored and graded at 24 h, 48 h, and on day 7 Post-MDA. Out of 10,010 enrolled study participants, 1621 participants reported a total of 3102 AEs during a seven-day follow-up. The cumulative incidence of AEs was 16.2% (95% CI, 15.5–16.9%). The proportion of participants who experienced one, two, or ≥three types of AEs was 9.2%, 4.6%, 2.4%, respectively. AEs were mild (87.3%), moderate (12.4%), and severe (0.3%) and resolved within 72 h. The five most common AEs were dizziness (5.9%), headache (5.6%), loss of appetite (3.3%), fever (2.9%), and drowsiness (2.6%). Older age, taking concurrent medications, ≥three tablets of DEC, and type of meal taken before MDA were significant predictors of AEs. One in six participants experienced systemic mild-to-moderate severity grading and transient AEs. DEC and ALB co-administration for the elimination of LF is generally safe and well-tolerated.

8 August 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
ABAbbie Barry
Abbie Barry
WOWyckliff Omondi
Wyckliff Omondi
EKElvis Kirui
Elvis Kirui
MOMARGARET ODECK OLUKA
MARGARET ODECK OLUKA
EAEleni Aklillu
Eleni Aklillu
Introduction Dual diethylcarbamazine and albendazole (DA) therapy is the standard mass drug administration (MDA) regimen for lymphatic filariasis in Kenya. Following the recent World Health Organization recommendation, Kenya piloted triple therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) in MDA. Objective We conducted a community-based, observational, cohort event monitoring study to compare the types, frequency, severity, and predictors of adverse events following dual versus triple therapy in 20,421 eligible residents. Methods Residents in Kilifi (n = 10,010) and Mombasa counties (n = 10,411) received DA and IDA through MDA campaigns, respectively. Adverse events were actively monitored through house-to-house visits on days 1, 2, and 7 after MDA. Any clinical events reported before and after MDA were cross-checked and verified to differentiate pre-existing events from MDA-associated adverse events. Results Overall, 5807 and 3102 adverse events were reported by 2839 and 1621 individuals in the IDA and DA groups, respectively. The incidence of experiencing one or more adverse events was significantly higher (p < 0.0001) in the IDA group (27.3%; 95% confidence interval [CI] 26.4–28.2) than in the DA group (16.2%; 95% CI 15.5–16.9). Dizziness (15.9% vs 5.9%) and drowsiness (10.1% vs 2.6%) were the most common adverse events and significantly higher in the IDA group compared with the DA group (p < 0.0001). Most adverse events were mild or moderate with a few severe cases (IDA = 0.05%; 95% CI 0.35–0.78, DA = 0.03%; 95% CI 0.14–0.60). Female sex, obesity, taking three or more diethylcarbamazine or ivermectin tablets, and having pre-existing clinical symptoms were significant predictors of adverse events following IDA treatment. Conclusions Ivermectin, diethylcarbamazine, and albendazole as a combination is as safe and well tolerated as DA to use in MDA campaigns with no serious life-threatening adverse events. Systemic mild-to-moderate adverse events with a few severe cases and transient adverse events are more common with IDA treatment than with DA treatment. Hence, integrating pharmacovigilance into a MDA program is recommended for the timely detection and management of adverse events.

20 August 2024 in Drug Safety
Verified
Journal Article
Open access
PDF file
EPEugene P. Van Puijenbroek
Eugene P. Van Puijenbroek
ABAbbie Barry
Abbie Barry
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
LNLazare Ntirenganya
Lazare Ntirenganya
TGTigist Dires Gebreyesus
Tigist Dires Gebreyesus
EAEleni Aklillu
Eleni Aklillu
Continuous professional development among stakeholders involved in drug safety monitoring and surveillance is imperative in strengthening pharmacovigilance (PV) systems. The “Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa” (PROFORMA) project aims to enhance the national PV infrastructure, post-marketing surveillance systems and clinical trial regulatory capabilities in Ethiopia, Tanzania, Kenya and Rwanda. To achieve this, training, including short-term training (STT) activities, at various levels is required. This article aims to describe the experiences of the authors during the development and implementation of STT in an attempt to improve the PV training landscape of these countries. To identify gaps, a baseline assessment of PV teaching and practices at the national medicines regulatory authorities (NMRAs) and medical universities was conducted. Five successive training sessions, tailored to each country's specific needs and regulatory environments, were conducted; three focusing on fundamental concepts in PV and two dedicated to training-of-trainers courses. The training targeted staff from PV units of the NMRAs and medical universities. Enabling participation from all four countries in the same training fostered cross-country learning and collaboration. The contribution of STT to university education and the operational methodologies within NMRAs are explored, showcasing the impact on knowledge transfer and skill development in each country. In conclusion, by investing strategically in STT activities and fostering partnerships with academic institutions and NMRAs, we demonstrated a sustainable approach to PV capacity strengthening in resource-limited settings. The success of this model underscores its potential for adoption and replication across the African continent, offering a valuable framework for strengthening drug safety regulation and ultimately protecting public health.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
CKCHRISTABEL KHAEMBA
CHRISTABEL KHAEMBA
ABAbbie Barry
Abbie Barry
WOWyckliff Omondi
Wyckliff Omondi
EKElvis Kirui
Elvis Kirui
MMMartha Mandale
Martha Mandale
EAEleni Aklillu
Eleni Aklillu
Background In Kenya Mass Drug Administration (MDA) intervention with single dose of Diethylcarbamazine Citrate (DEC) and Albendazole (ABC) commonly referred to as DA. has been in use since 2002 the control of Lymphatic Filariasis(LF), however no safety surveillance has been conducted before. Recently, the Neglected Tropical Disease (NTD) Program, piloted the use of Ivermectin (IVM), Diethylcarbamazine and Albendazole known as IDA triple therapy in two highly endemic counties. Methodology This was a longitudinal community-based cohort event monitoring 10,010 and 10, 411 eligible participants in Kilifi and Mombasa Counties respectively. Adverse event monitoring and grading was actively done at 24 hours, 48 hours and at day 7 following mass drug administrations. The collected data was analysed for incidence, types, and predictors of adverse events. Results A total of 5807 and 3102 AEs were reported by 2839 and 1621 individuals in the IDA and DA groups, respectively. The incidence of experiencing one or more AEs was significantly higher (p<0.0001) in IDA (27.3%; 95%CI, 26.4%-28.2%) compared to DA (16.2%;95%CI, 15.5–16.9%) group. The three most AEs reported among those who took IDA were dizziness (15.9%), drowsiness (10.10%) and headache (6.5%), compared to DA that reports dizziness (5.9%), headache (5.6%) and loss of appetite (3.3%). Female sex, taking ≥ 3 tablets of DEC or IVM, older age, taking concurrent medications, ≥3 tablets of DEC, and type of meal taken before MDA were significant predictors of AEs. The AEs were systemic, mild to moderate and transient. Conclusion Both the dual Therapy with DA and triple therapy with IDA were generally safe and well as MDA regimens for Elimination of LF. The incidence of experiencing one or more type AEs is about two-fold higher with IDA than with DA. The integration of safety monitoring during MDA is critical for the timely detection and management of reported AEs.